Updated: July 18, 2012 11:30 a.m.
OptiMedica Corp. is making waves and challenging the leaders in global eye care with its Catalys Precision Laser system for cataract surgery and CEO Mark Forchette isn’t shy about extolling his company’s potential.
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Updated: July 18, 2012 11:30 a.m.
OptiMedica Corp. is making waves and challenging the leaders in global eye care with its Catalys Precision Laser system for cataract surgery and CEO Mark Forchette isn’t shy about extolling his company’s potential.
Eye care goliath Bausch & Lomb may be looking to go public this year, a move that would signal renewed confidence in the company following a bit of a rough patch.
Bausch was taken private in 2007 by Warburg Pincus for $4.5 billion after accounting discrepancies forced the company to restate its earnings and contaminated contact disinfectant solution resulted in a high-profile recall.
The FDA issued a message via Twitter to fans of the young adult "Twilight" series attending the official convention in San Antonio in August, cautioning them against non-regulated custom contact lenses that let them imitate their "fave vampire."
"Want 2 look like your fave vampire?" the federal watchdog agency tweeted. "C an eye doctor before buying costume/fashion lenses."
The FDA said it gave pre-market approval to Glaukos Corp. to market its iStent device in the U.S. for cataract surgeries.
House, nursing home fires spur Nidek oxygen concentrator recall
Alabama-based oxygen devices maker Nidek Medical pulled its Mark5 Nuvo oxygen concentrators off of shelves after receiving reports of fires in homes and nursing homes, according to an FDA release.
By Rob Kinslow, Sr. Strategist, Brand Communication, KHJ Brand Activation
I’m seeing much more clearly since I visited my eye doctor.
Oh, I haven’t gotten my new vision prescription filled yet. Thanks to my near-blindness, new spectacles knock me back the equivalent of taking the family to see a doubleheader at Fenway Park. (Yeah, that much.) So I’m waiting for a windfall.
Consumer Union demanded that a new user fee deal the medical device industry brokered with the FDA include more stringent oversight of med-tech makers.
"We shouldn’t be used as guinea pigs when it comes to something as serious as a medical implant," according to the organization’s website. "Medical devices should not be ticking time bombs!"
Cutera Inc. (NSDQ:CUTR) entered into a binding agreement with Mountain View, Calif.-based Iridex (NSDQ:IRIX) to purchase parts of its global aesthetic business arm for $5.1 million.
The deal is expected to advance Cutera’s place in the $1 billion global aesthetic business market, expanding the company’s presence in the vascular aesthetic sector while allowing Iridex room to focus on laser eye treatments.
Avedro Inc. won an orphan drug designation for a solution used with its KXL irradiation system to treat corneal ectasia following refractive surgery.
The decision sets the Waltham, Mass.-based company up for 7 years of exclusive rights to the U.S. market if the technology pans out.
The VibeX ophthalmic solution is used with the company’s UVA radiation system for corneal cross-linking to treat corneal ectasia following refractive eye surgeries such as Lasik.